Adds Global Particle Size Technology Leader
to Industry’s Broadest Bioavailability and Delivery Technology
Offerings
Catalent, Inc. (NYSE:CTLT), the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced that it has
acquired Micron Technologies, a leading global provider of particle
size engineering technologies.
In an important advance in executing its strategy to provide the
best drug delivery technologies and the broadest drug development
expertise, Catalent will add Micron Technologies’ superior particle
size engineering capabilities to its industry leading suite of drug
delivery and development solutions. Catalent can now partner with
more pharmaceutical innovators at the earliest stages of the drug
development process with an unrivaled set of options and expertise.
These range from OptiForm® API optimization and Micron Technologies
particle size optimization, to expert formulation and final dose
form design services, through to leading bioavailability solutions
such as RP Scherer Softgel lipid systems and OptiMelt™ hot melt
extrusion technologies. Catalent can support its customers all the
way through scale up, clinical and commercial manufacturing of
finished oral and inhaled dose forms around the world, including
for highly potent compounds.
“This strategic acquisition allows Catalent to provide an
unprecedented set of integrated development solutions and superior
drug delivery technologies to the industry, partnering with our
customers’ R&D teams earlier in the development cycle and
helping them deliver better treatments to clinic and to market
faster and more efficiently,” said John Chiminski, Catalent, Inc.
President and CEO. “We are pleased to add Micron Technologies’
leading technologies and manufacturing expertise and welcome their
highly talented management, scientific and operations teams to
Catalent.”
Micron Technologies adds to Catalent’s long history of
innovation and leadership in the pharmaceutical industry, with its
proven and versatile portfolio of particle size reduction,
micronization and milling technologies used to overcome
bioavailability, stability and manufacturability challenges.
The acquisition is Catalent’s second since its IPO in July, and
follows the acquisition of Redwood Bioscience, with its SMARTag™
Antibody-Drug Conjugate (ADC) technology platform, in October
2014.
Micron Technologies currently operates two state-of-the-art
facilities, with excellent quality and regulatory compliance
records, in Malvern, PA, and in Dartford, U.K., and employs
approximately 100 people across both sites. Micron Technologies has
over 25 years of experience in air jet milling micronization and is
capable of processing R&D and commercial volumes at both of its
sites. Micron Technologies currently supports active programs
involving over 300 customers from around the world. Both facilities
are equipped with advanced systems to ensure the quality, safety
and total containment of highly potent and cytotoxic compounds, and
provide integrated analytical services capabilities from early
stage development to commercialization.
Joseph Drost, CEO of Micron Technologies, who will continue to
lead this business, remarked, “We are excited to become part of
Catalent, as there is a natural synergy between our organizations,
with the global leader in advanced delivery technologies and
development solutions now joining forces with a leading provider of
particle size engineering technologies and integrated analytical
services. Through access to Catalent’s global network, development
expertise and innovative technologies, we can jointly provide
end-to-end solutions to accelerate drug development programs and
bring better treatments to patients worldwide.”
About Catalent, Inc.
Catalent, Inc. is the leading global provider of advanced
delivery technologies and development solutions for drugs,
biologics and consumer health products. With over 80 years serving
the industry, Catalent has proven expertise in bringing more
customer products to market faster, enhancing product performance
and ensuring reliable clinical and commercial product supply.
Catalent employs approximately 8,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents, and in
fiscal 2014 generated more than $1.8 billion in annual revenue.
Catalent is headquartered in Somerset, N.J.
For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
About Micron Technologies
Micron Technologies, a portfolio company of Arlington Capital
Partners, is a leading global provider of particle size engineering
technologies for the pharmaceutical industry. Micron Technologies
has helped overcome bioavailability, stability and
manufacturability challenges across hundreds of oral and inhaled
drugs for over 25 years through its leading, proven and versatile
portfolio of particle size reduction, micronization and milling
technologies. Micron Technologies employs approximately 100 people
across 2 facilities in the U.S. and the U.K. Micron Technologies is
headquartered in Malvern, PA.
For more information, visit www.microntech.com
Forward-Looking Statements
This press release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”,
“likely”, “may”, “will”, “would” or other words or phrases with
similar meanings. Similarly, statements that describe our
Catalent’s objectives, plans or goals are, or may be,
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Catalent, Inc.’s expectations
and projections. Some of the factors that could cause actual
results to differ include, but are not limited to, the following:
general industry conditions and competition; product or other
liability risk inherent in the design, development, manufacture and
marketing of our offerings; inability to enhance our existing or
introduce new technology or services in a timely manner; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; and our substantial debt and debt service requirements
that restrict our operating and financial flexibility and impose
significant interest and financial costs; or difficulty in
integrating Micron Technologies into Catalent’s existing business,
thereby reducing or eliminating the anticipated benefits of the
transaction. For a more detailed discussion of these and other
factors, see the information under the caption “Risk Factors” in
its Annual Report on Form 10-K for the fiscal year ended June 30,
2014 filed with the Securities and Exchange Commission. All
forward-looking statements in this release speak only as of the
date of this release or as of the date they are made, and Catalent,
Inc. does not undertake to update any forward-looking statements as
a result of new information or future events or developments unless
except to the extent required by law.
Media:Chris Halling, +44 (0)7580
041073chris.halling@catalent.comorRichard Kerns, +44 (0)161 728
5880richard@nepr.euorInvestor Relations:Bertner Advisors,
LLCMonique Kosse, +1 860 940
0352Monique.Kosse@BertnerAdvisors.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024